Entelexo Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Early Stage VC

  • Latest Deal Amount
  • $50K

  • Investors
  • 5

Entelexo General Information

Description

Developer of modern treatments designed to assist immune-mediated diseases. The company specializes in creating a new class of drugs which include extracellular vesicles that are derived from stem cells, enabling healthcare workers to treat autoimmune diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 5270 California Avenue
  • Suite 300
  • Irvine, CA 92617
  • United States
+1 (510)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Vertical(s)
Corporate Office
  • 5270 California Avenue
  • Suite 300
  • Irvine, CA 92617
  • United States
+1 (510)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Entelexo Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Early Stage VC 23-May-2023 $50K Completed Pre-Clinical Trials
6. Accelerator/Incubator 15-Oct-2021 Completed Pre-Clinical Trials
5. Equity Crowdfunding 01-Jul-2021 Completed Pre-Clinical Trials
4. Seed Round 28-May-2021 Completed Pre-Clinical Trials
3. Accelerator/Incubator 06-Mar-2021 Completed Pre-Clinical Trials
2. Angel (individual) 01-Oct-2020 $278K $428K Completed Startup
1. Angel (individual) 01-Jun-2020 $150K $150K Completed Startup
To view Entelexo’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Entelexo Patents

Entelexo Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2023250440-A1 Engineered extracellular vesicles for therapeutic delivery Inactive 22-Jun-2022
WO-2023076418-A2 Platforms, compositions, and methods for therapeutic delivery Inactive 26-Oct-2021
WO-2023076418-A3 Platforms, compositions, and methods for therapeutic delivery Inactive 26-Oct-2021
WO-2022133301-A1 Platforms, compositions, and methods for therapeutic delivery Inactive 18-Dec-2020
AU-2020298314-A1 Platforms, compositions, and methods for therapeutics delivery Inactive 21-Jun-2019 C07K14/70521
To view Entelexo’s complete patent history, request access »

Entelexo Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Entelexo Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Endless Frontier Labs Accelerator/Incubator Minority
Acequia Capital Venture Capital Minority
Founders, Inc Venture Capital Minority
Metaplanet Holdings Venture Capital Minority
Y Combinator Accelerator/Incubator Minority
To view Entelexo’s complete investors history, request access »

Entelexo FAQs

  • When was Entelexo founded?

    Entelexo was founded in 2020.

  • Where is Entelexo headquartered?

    Entelexo is headquartered in Irvine, CA.

  • What is the size of Entelexo?

    Entelexo has 4 total employees.

  • What industry is Entelexo in?

    Entelexo’s primary industry is Drug Discovery.

  • Is Entelexo a private or public company?

    Entelexo is a Private company.

  • What is Entelexo’s current revenue?

    The current revenue for Entelexo is .

  • How much funding has Entelexo raised over time?

    Entelexo has raised $2.64M.

  • Who are Entelexo’s investors?

    Endless Frontier Labs, Acequia Capital, Founders, Inc, Metaplanet Holdings, and Y Combinator have invested in Entelexo.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process